Biotech
GSK Buys New Cancer Drug
GSK is paying a lot of money to get a new cancer drug from Hutchmed, hoping to help patients with tough-to-treat tumors.
A big drug company, GSK, just made a deal. They are buying a new cancer medicine from Hutchmed. This medicine is special. It targets two hard parts of cancer called KRAS and EGFR.
GSK pays Hutchmed $110 million right away. They could pay up to $1.295 billion more later. This happens if the drug does well. The medicine is still new, but it shows promise for some cancers.
This deal helps GSK grow its cancer drug business. It could lead to new ways to fight cancer. Patients facing these difficult cancers may get new hope. GSK wants to bring this important drug to people who need it.
Source: FierceBiotech
More from Biotech
